Inovio

528 articles about Inovio

• INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

  6/27/2022

  INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO).

• INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022

  5/27/2022

  INOVIO's DNA medicines immunotherapy in combination with Libtayo ® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients.

• INOVIO to Present at Jefferies 2022 Healthcare Conference

  5/23/2022

  INOVIO  today announced that Jacqueline Shea , Ph .D., President and CEO, and Jeffrey Skolnik , M .D., SVP of Clinical Development for Oncology and HPV Therapeutics, are scheduled to participate in a fireside chat and 1x1 investor meetings at the Jefferies 2022 Healthcare Conference on Wednesday, June 8th, 2022 at 1:00 PM EDT.

• INOVIO Reports First Quarter 2022 Financial Results and Program Developments

  5/10/2022

  INOVIO reported financial results for the quarter ended March 31, 2022 and announced recent program and corporate developments.

• INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer

  5/10/2022

  INOVIO announced the appointment of Jacqueline Shea, Ph.D., as President and Chief Executive Officer of INOVIO, effective immediately.

• INOVIO to Report First Quarter 2022 Financial Results on May 10, 2022

  4/26/2022

  INOVIO (NASDAQ: INO) announced today that first quarter 2022 financial results will be released after the market close on May 10, 2022.

• INOVIO to Present at Oppenheimer's 32nd Annual Healthcare Conference

  3/8/2022

  INOVIO announced that Dr. J. Joseph Kim, President and CEO, will participate in a fireside chat and 1x1 investor meetings at Oppenheimer's 32nd Annual Healthcare Conference on Tuesday, March 15, 2021.

• INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results

  3/1/2022

  INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today reported financial results for the quarter and year ended December 31, 2021.

• INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022

  2/15/2022

   INOVIO (NASDAQ: INO) announced today that fourth quarter 2021 financial results will be released after the market close on March 1, 2022.

• INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18

  12/14/2021

  INOVIO today announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL).

• INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants

  11/30/2021

  INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, announced the company is rapidly moving to evaluate its COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging B.1.1.529 variant of concern.

• INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference

  11/15/2021

  INOVIO announced today that eight company-sponsored presentations will be given this week at the 34th International Papillomavirus Conference (IPVC) , which is being held virtually from today, November 15 through Friday, November 19.

• INOVIO Reports Third Quarter 2021 Financial Results

  11/9/2021

  INOVIO, a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat people with cancer, and HPV-associated diseases, reported financial results for the quarter ended September 30, 2021.

• INOVIO Expands Executive Leadership to Prepare for Commercial Operations

  11/5/2021

  INOVIO today announced the strategic appointments of new leaders designed to position INOVIO for growth and upcoming commercial operations.

• INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India

  11/3/2021

  Authorization to conduct INNOVATE Phase 3 trial in India builds on recent regulatory authorizations from Brazil, Philippines, Mexico and Colombia

• 

  Inovio and AstraZeneca Terminate Six-Year-Old DNA Cancer Vaccine Program

  11/1/2021

  Inovio shares are down about 2% in premarket trading after cancellation reports of a DNA cancer vaccine collab with AstraZeneca.

• INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021

  10/27/2021

  INOVIO (NASDAQ: INO) announced today that third quarter 2021 financial results will be released after the market close on November 9, 2021

• INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa

  10/26/2021

  INOVIO today announced its Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, completed full enrollment of 220 participants.

• INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives

  10/21/2021

  INOVIO today announced the signing of a non-binding memorandum of understanding (MOU) with Colombia's Ministry of Health and Social Protection reflecting the intent to advance efforts to combat the pandemic and endemic threat posed by COVID-19  and to better prepare for future public health emergencies.

• INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800

  10/12/2021

  INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the online preprint publication in MedRxiv of Phase 1 clinical data on homologous boosting of its COVID-19 DNA vaccine candidate, INO-4800.